Loading...
XNAS
SCYX
Market cap26mUSD
Oct 08, Last price  
4.22USD
1D
-11.72%
1Q
-3.65%
Jan 2017
-98.35%
IPO
-99.40%
Name

SCYNEXIS Inc

Chart & performance

D1W1MN
XNAS:SCYX chart
P/E
—
P/S
1.29
EPS
—
Div yield, %
—
Shrs. gr., 5y
36.03%
Rev. gr., 5y
98.68%
Revenues
21m
+449.95%
16,837,00016,857,0001,256,000257,000257,000257,000257,000121,000013,163,0005,091,000140,141,0003,746,00020,601,000
Net income
-9m
L-59.56%
-11,477,000-30,461,000-4,234,000-32,623,000-29,989,000-25,060,000-12,468,000-53,710,000-55,185,000-32,866,000-62,809,00067,041,000-21,288,000-8,609,000
CFO
-5m
L-78.00%
-10,596,000-4,307,000-9,472,000-24,545,000-29,353,000-24,556,000-28,323,000-38,119,000-49,354,000-54,560,000-79,883,00060,159,000-24,009,000-5,283,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.

Key people

Marco Taglietti
President, Chief Executive Officer, Director · since 2015
Eric S Francois
Chief Financial Officer · since 2015
Nkechi Azie
Vice President - Clinical Development · since 2019
Scott A. Sukenick
General Counsel · since 2017
David Angulo
Chief Medical Officer · since 2015
Laurent Arthaud
Director · since 2007
David C. Hastings
Director · since 2015
Patrick J Langlois
Director · since 2006
Guy Macdonald
Director · since 2014
Jean-Yves Nothias
Director · since 2000
Philippe Tinmouth
Director · since 2019
URL
https://www.scynexis.com/
IPO date
May 02, 2014
Employees
36
Domiciled in
US
Incorporated in
US
Legal address
c/o CORPORATION SERVICE COMPANY, 251 LITTLE FALLS DRIVE
WILMINGTON, DE 19808
US
Headquarters
1 Evertrust Plaza, 13th Floor
Jersey City, NJ 07302
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT